Physician profile
Alaba Devonne Robinson
NPI 1508870353
$16,725.32
in general payments reported to CMS, 2019-2025
41 companies · $1,208 in 2025
The $1,208 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,034 · 2020: $1,630 · 2021: $3,436 · 2022: $2,909 · 2023: $2,859 · 2024: $1,649 · 2025: $1,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,715.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,448.28 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $2,098.68 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,341.14 | 2019-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $1,293.97 | 2019-2023 | Xarelto, Spravato |
| Glaxosmithkline, LLC. | $1,269.52 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $947.07 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Pfizer INC. | $872.90 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $693.05 | 2021-2025 | |
| Abbvie INC. | $653.90 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Merck Sharp & Dohme LLC | $488.23 | 2019-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Sanofi-Aventis U.S. LLC | $474.19 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $414.03 | 2021 | |
| Novartis Pharmaceuticals Corporation | $374.13 | 2019-2023 | |
| Amgen INC. | $371.07 | 2019-2023 | Repatha, Otezla |
| Esperion Therapeutics, INC. | $328.09 | 2021-2025 | Nexletol |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alaba Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.